Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCR | P30988 | 4/20 | 0.65 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.59 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.59 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.59 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.58 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.57 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30586591 | 0.87 | CALCR (0.58) | CALCRKEAP1OPRD1NTSR1 | |
| SCHEMBL29414492 | 0.86 | CALCR (0.68) | CALCRKEAP1 | |
| SCHEMBL30938249 | 0.86 | CALCR (0.68) | CALCRKEAP1 | |
| SCHEMBL29370426 | 0.86 | CALCR (0.67) | CALCRKEAP1 | |
| SCHEMBL30938250 | 0.86 | CALCR (0.67) | CALCRKEAP1 | |
| SCHEMBL30668489 | 0.85 | CALCR (0.63) | CALCR | |
| SCHEMBL31182792 | 0.85 | CALCR (0.76) | CALCRCRHR1CRHR2HCRTR1HCRTR2 | |
| SCHEMBL30862326 | 0.84 | CALCR (0.70) | CALCRCRHR1CRHR2HCRTR1HCRTR2 | |
| SCHEMBL31633285 | 0.84 | CALCR (0.60) | CALCR | |
| SCHEMBL30658358 | 0.84 | CALCR (0.77) | CALCRCRHR1CRHR2HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240358798-A1 | TREATMENT FOR SARS-COV-2 AND OTHER CORONAVIRUSES | SHEVY DRORA (US) | 2024-10-31 | — | — | US | claimed |
| US-20230127487-A1 | ASSESSING AND TREATING ACUTE DECOMPENSATED HEART FAILURE | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2023-04-27 | — | — | US | claimed |
| EP-4117692-A1 | ASSESSING AND TREATING ACUTE DECOMPENSATED HEART FAILURE | Mayo Foundation for Medical Education and Research (US) | 2023-01-18 | — | — | EP | claimed |
| US-20220362344-A1 | TREATMENT FOR SARS-COV-2 AND OTHER CORONAVIRUSES | SHEVY DRORA (US) | 2022-11-17 | — | — | US | claimed |
| US-11419917-B2 | Treatment for SARS-CoV-2 and other coronaviruses | SHEVY DRORA (US) | 2022-08-23 | — | — | US | claimed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-03-12 | — | — | US | disclosed |
| US-20250361282-A1 | ATRIAL NATRIURETIC PEPTIDE ENGRAFTED ANTIBODIES | BAYER AKTIENGESELLSCHAFT (DE) | 2025-11-27 | — | — | US | disclosed |
| US-12390508-B2 | Brain natriuretic peptide engrafted antibodies | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-08-19 | — | — | US | disclosed |
| US-20250236654-A1 | C-TYPE NATRIURETIC PEPTIDE ENGRAFTED ANTIBODIES | BAYER AKTIENGESELLSCHAFT (DE) | 2025-07-24 | — | — | US | disclosed |
| EP-3256446-B1 | (2S,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-4-(ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID AS NEPRILYSIN INHIBITOR | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-3099668-B1 | 5-BIPHENYL-4-HETEROARYLCARBONYLAMINO-PENTANOIC ACID DERIVATIVES AS NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2022-05-04 | — | — | EP | disclosed |
| US-20220106300-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-04-07 | — | — | US | disclosed |
| EP-3966201-A1 | THIOSEMICARBAZATES AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3966223-A1 | PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| CN-114126619-A | Compounds for the synthesis of peptidomimetics | 范因斯坦医学研究院 | 2022-03-01 | — | — | CN | disclosed |
| US-11261197-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-03-01 | — | — | US | disclosed |
| WO-2022031914-A2 | METHODS OF TREATING CARDIAC DISORDERS AND CONGESTIVE HEART FAILURE AND ADMINISTERING AAV VECTORS | ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | CALCR 2542/4885KEAP1 3540/4885CRHR1 513/4885 |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | NPR1, NGLY1, DDAH1 | CALCR 1358/4885KEAP1 1438/4885CRHR1 46/4885 |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | TST, THRB, HSPB1 | CALCR 1795/4885KEAP1 3609/4885CRHR1 1521/4885 |
| US-11261197-B2 | Neprilysin inhibitors | MME, REN, ACE | CALCR 342/4885KEAP1 1040/4885CRHR1 198/4885 |
| US-20220106300-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | CALCR 237/4885KEAP1 1604/4885CRHR1 155/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | CALCR 1581/4885KEAP1 3528/4885CRHR1 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.